Promising novel treatment for Dry Eye Disease revealed by new research
Manchester, United Kingdom, 13 January 2022 – The University of Manchester, Seoul National University College of Medicine and Link Biologics Limited today announced that promising preclinical data on the treatment of Dry Eye Disease using a novel protein biological drug, Link_TSG6, have been published in the peer-reviewed journal, Ocular Surface. Dry Eye Disease (DED) is the most […]
Promising novel treatment for Osteoarthritis revealed by new research
Manchester, United Kingdom, 5 June 2023 – The University of Manchester and Link Biologics Limited today announced the publication of preclinical data on a potential new treatment for Osteoarthritis in the peer-reviewed journal, Osteoarthritis and Cartilage. This paper describes the development of a protein biological drug termed Link_TSG6 with disease modifying properties. Osteoarthritis (OA) is the […]
Link Biologics and Théa Open Innovation enter partnership to develop Link_TSG6 for Dry Eye Disease
London, United Kingdom, 12 September 2023 – Link Biologics Limited and Théa Open Innovation today announced that they have entered into an agreement to co-develop Link_TSG6 for the treatment of Dry Eye Disease (DED) and other ophthalmology indications, worldwide excluding Asia. Link_TSG6 is a biological drug based on human TSG-6, a protein that has an […]
Link Biologics founder Tony Day elected to Academy of Medical Sciences
London, United Kingdom, 22 May 2025 Congratulations to our co-founder Professor Tony Day who has been elected as a Fellow of the Academy of Medical Sciences! Click the links below to read more:Manchester professors become new Academy of Medical Sciences FellowsAcademy of Medical Sciences announces new Fellows for 2025 For media enquiries contact:info@linkbiologics.co.uk
